Loading
Latest filing published 01 Aug 2023 for Spectrum Pharmaceuticals INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Juhyun Lim (board member) discloses dealings in Spectrum Pharmaceuticals Inc to SEC (Form 4). In total, 3 filings cover trades dated from 25 March 2022 to 31 July 2023.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 1 August 2023, the filings show a transaction in Spectrum Pharmaceuticals Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations